10 Einträge gefunden

1. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT

   1. Engler, Tobias
   2. Fasching, Peter A
   3. Lüftner, Diana
   4. Hartkopf, Andreas D
   5. Müller, Volkmar
   6. Kolberg, Hans-Christian
   7. Hadji, Peyman

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry

   1. Müller, Volkmar
   2. Hein, Alexander
   3. Hartkopf, Andreas D
   4. Fasching, Peter A
   5. Kolberg, Hans-Christian
   6. Hadji, Peyman
   7. Tesch, Hans

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

   1. Hein, Alexander
   2. Hartkopf, Andreas D
   3. Emons, Julius
   4. Lux, Michael P
   5. Volz, Bernhard
   6. Taran, Florin-Andrei
   7. Overkamp, Friedrich

   2021 - Forschungsinformationssystem des UKE
5. Update Breast Cancer 2020 Part 1 - Early Breast Cancer:Consolidation of Knowledge About Known Therapies

   1. Schneeweiss, Andreas
   2. Hartkopf, Andreas D
   3. Müller, Volkmar
   4. Wöckel, Achim
   5. Lux, Michael P
   6. Janni, Wolfgang
   7. Ettl, Johannes

   2020 - Forschungsinformationssystem des UKE
6. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2020 - Forschungsinformationssystem des UKE
7. Update Breast Cancer 2020 Part 3 - Early Breast Cancer

   1. Huober, Jens
   2. Schneeweiss, Andreas
   3. Hartkopf, Andreas D
   4. Müller, Volkmar
   5. Lux, Michael P
   6. Janni, Wolfgang
   7. Ettl, Johannes

   2020 - Forschungsinformationssystem des UKE
8. Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer:New Treatments and Implementation of Therapies with Companion Diagnostics

   1. Lüftner, Diana
   2. Schneeweiss, Andreas
   3. Hartkopf, Andreas D
   4. Müller, Volkmar
   5. Wöckel, Achim
   6. Janni, Wolfgang
   7. Ettl, Johannes

   2020 - Forschungsinformationssystem des UKE
9. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

   1. Michel, Laura L
   2. Hartkopf, Andreas D
   3. Fasching, Peter A
   4. Kolberg, Hans-Christian
   5. Hadji, Peyman
   6. Tesch, Hans
   7. Häberle, Lothar

   2020 - Forschungsinformationssystem des UKE
10. Update Breast Cancer 2017 - Implementation of Novel Therapies

    1. Lux, Michael P
    2. Janni, Wolfgang
    3. Hartkopf, Andreas D
    4. Nabieva, Naiba
    5. Taran, Florin-Andrei
    6. Overkamp, Friedrich
    7. Kolberg, Hans-Christian

    2017 - Forschungsinformationssystem des UKE